Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does tumor mutational status correlate with clinical response to imatinib?

Nature Clinical Practice Oncology volume 3, pages 600–601 (2006)Cite this article

boxed-textDebiec-Rychter M et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093–1103

Molecular analysis of GISTs provides useful information for predicting the clinical response to imatinib and may be helpful for individualizing dosage

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Corless CL et al. (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813–3825

    Article  CAS  Google Scholar 

  2. Debiec-Rychter M et al. (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689–695

    Article  CAS  Google Scholar 

  3. Heinrich MC et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342–4349

    Article  CAS  Google Scholar 

  4. Verweij J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127–1134

    Article  CAS  Google Scholar 

  5. Heinrich M et al. (2006) Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status [abstract]. ASCO Annual Meeting Proceedings. 24: 520S–520S

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine at Oregon Health & Science University and Head of Hematology & Medical Oncology at the Portland VA Medical Center,

    Michael C Heinrich

  2. CL Corless serves as Professor and Vice-Chair of Pathology at the Oregon Health & Science University, Portland, OR, USA

    Christopher L Corless

Authors
  1. Michael C Heinrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher L Corless
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael C Heinrich.

Ethics declarations

Competing interests

Christopher Corless and Michael Heinrich have received research support from and are consultants for Novartis and Pfizer, and are also members of the Speaker's Bureau for Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heinrich, M., Corless, C. Does tumor mutational status correlate with clinical response to imatinib?. Nat Rev Clin Oncol 3, 600–601 (2006). https://doi.org/10.1038/ncponc0639

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0639

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing